A Phase 1/2 interventional study of Revumenib and Chemotherapy in Colorectal Cancer and Solid Tumors, sponsored by Syndax Pharmaceuticals. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Syndax Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.
Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 1,202nd largest by enrollment of the 1,932 interventional ones that give a count, is one of 139 that started in 2023, is one of 266 in phase 1/2, and was the 1,861st registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 40–80 · Men only
Full-Life Technologies UK Limited · Sites in United States, Australia, China
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,339 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 817 · Phase 2 791 · Phase 3 132 · Phase 4 19
First in 1981; this study’s year is marked. 139 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 64 across the 1,932 interventional studies, 221 across the 324 observational. Of the 1,562 that completed or were terminated, 550 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
885 of 2,339 have an industry lead sponsor. The 10 most frequent:
Syndax Pharmaceuticals is the lead sponsor of 31 studies on the registry; 4 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Syndax Pharmaceuticals has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
228 of the studies in Colorectal Neoplasms with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05141721Phase 3Seattle Project CorporationA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | 2027-03 |
| NCT04428905Phase 3City of Hope Medical CenterSelf-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | 2027-03-31 |
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT01349881Phase 3SWOG Cancer Research NetworkS0820, Adenoma and Second Primary Prevention Trial | 2027-09-15 |
| NCT03796884Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityLinaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | 2026-11 |
Add all 228 to your calendar (.ics) → With an account.
Among the 2,339 studies in Colorectal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.
The study will be conducted in two parts. The Phase 1 portion of the study consists of a dose escalation cohort, and a signal-seeking expansion where anti-tumor activity signals will be evaluated. The Phase 2 portion of the study will further confirm the anti-tumor activity signals of revumenib.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive revumenib tablets or capsules three times a day (TID) or two times a day (BID) from Day 1 of each 28-day cycle.
Drug: Revumenib
Participants will receive revumenib tablets TID or BID from Day 1 of each 28-day cycle.
Drug: Revumenib
Participants will receive revumenib tablets TID or BID from Day 1 of each 28-day cycle.
Drug: Revumenib
Participants will receive chemotherapy from Day 1 of each 28-day cycle.
Drug: Chemotherapy
Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
Also known as: SNDX-5613
Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
Phase 1a: Number of Participants Experiencing Dose Limiting Toxicities (DLTs)
DLT was defined as any of the following occurring in Cycle 1: Grade 4 neutropenia (absolute neutrophil count \[ANC\] \<500 cells/mm\^3) unresolved to Grade 2 (ANC \>1500 cells/mm\^3) or baseline for more than 7 consecutive days in the absence of growth factor support, ≥Grade 3 neutropenia (ANC \<1000 cells/mm\^3) with a single temperature of \>38.3°Celsius (101°Fahrenheit) or a sustained temperature of ≥38°Celsius (100.4°Fahrenheit) for more than 1 hour, Grade 4 thrombocytopenia (\<25,000/mm\^3) of any duration, ≥Grade 3 thrombocytopenia (\<50,000/mm\^3) with clinically significant bleeding, Grade 4 anemia (i.e, life-threatening consequences; urgent intervention indicated) or ≥Grade 3 nonhematologic toxicity as defined in Common Terminology Criteria for Adverse Events version 5.0 scale where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, medically significant, Grade 4=Life-threatening and 5=Death.
Time frame: Day 1 up to Day 28
Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study intervention, whether or not considered related to the study intervention. TEAEs were defined as those having an onset on or after the first dose of revumenib or a sign, symptom, or a diagnosis that worsened on or after first dose of revumenib but no later than 30 days after the date of the last dose of revumenib. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to 2.2 years
Phase 1: Disease Control Rate (DCR)
DCR was defined as the percentage of participants with objective evidence of confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) according to Response Evaluation in Solid Tumors (RECIST) version 1.1 criteria as assessed by the investigator. CR=disappearance of all target lesions; disappearance of non-target lesions. PR=At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. PD=At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
Time frame: Up to 2.2 years
Phase 1: Overall Response Rate (ORR)
ORR was defined as the percentage of participants who achieved a best overall response of PR or CR according to RECIST v1.1 criteria as assessed by the investigator. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. CR=Disappearance of all target lesions; disappearance of all nontarget lesions.
Time frame: Up to 2.2 years
Phase 2: Progression Free Survival (PFS)
PFS was defined as the time from the first dosing date to the first documented progression or death due to any cause, whichever occurred first.
Time frame: Up to 2.2 years
Phase 1a: Maximum Plasma Concentration (Cmax) of Revumenib
Time frame: Cycle 1 Day 7, Cycle 1 Day 14, Cycle 2 Day 8, Cycle 2 Day 15, Cycle 5 Day 1 (Cycle length=28 days)
Phase 1b: Maximum Plasma Concentration (Cmax) of Revumenib
Time frame: Cycle 1 Day 7, Cycle 1 Day 14, Cycle 2 Day 8, Cycle 2 Day 15 (Cycle length=28 days)
Phase 1a: Area Under the Plasma Concentration Versus Time Curve (AUC0-t) of Revumenib
Time frame: Cycle 1 Day 7, Cycle 1 Day 14, Cycle 2 Day 8, Cycle 2 Day 15, Cycle 5 Day 1 (Cycle length=28 days)
Phase 1a: Time to Maximum Plasma Concentration (Tmax) of Revumenib
Time frame: Cycle 1 Day 7, Cycle 1 Day 14, Cycle 2 Day 8, Cycle 2 Day 15, Cycle 5 Day 1 (Cycle length=28 days)
Phase 1b: Time to Maximum Plasma Concentration (Tmax) of Revumenib
Time frame: Cycle 1 Day 7, Cycle 1 Day 14, Cycle 2 Day 8, Cycle 2 Day 15 (Cycle length=28 days)
Phase 1b: Area Under the Plasma Concentration Versus Time Curve (AUC0-t) of Revumenib
Time frame: Cycle 1 Day 7, Cycle 1 Day 14, Cycle 2 Day 8, Cycle 2 Day 15 (Cycle length=28 days)
Phase 2: Area Under The Concentration Time Curve of Revumenib
Time frame: Up to 2.2 years
Phase 2: Maximum Plasma Concentration (Cmax) of Revumenib
Time frame: Up to 2.2 years
Phase 2: Time to Maximum Plasma Concentration (Tmax) of Revumenib
Time frame: Up to 2.2 years
Phase 2: Number of Participants With TEAEs
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study intervention, whether or not considered related to the study intervention. TEAEs were defined as those having an onset on or after the first dose of revumenib or a sign, symptom, or a diagnosis that worsened on or after first dose of revumenib but no later than 30 days after the date of the last dose of revumenib. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to 2.2 years
Phase 2: Overall Survival (OS)
OS was defined as the time from the date of first dosing of revumenib to death due to any cause.
Time frame: Up to 2.2 years
Phase 2: Disease Control Rate (DCR) at 6 Cycles (28-Day Cycles) as Assessed by Blinded Radiographic Review
DCR was defined as the percentage of participants with objective evidence of confirmed CR, confirmed PR, or SD according to RECIST version 1.1 criteria as assessed by blinded radiographic review. CR=disappearance of all target lesions; disappearance of non-target lesions. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. PD=At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
Time frame: Up to 2.2 years
Phase 2: ORR as Assessed by Blinded Radiographic Review
ORR was defined as the percentage of participants who achieved a best overall response of PR or CR according to RECIST v1.1 criteria as assessed by blinded radiographic review. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. CR=Disappearance of all target lesions; disappearance of all nontarget lesions.
Time frame: Up to 2.2 years
Phase 2: Duration of Response (DOR) as Assessed by Blinded Radiographic Review
DOR was defined as the time from the first documented response (CR or PR) to the first documented objective PD or death due to any case according to RECIST v1.1 criteria as assessed by blinded radiographic review. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. CR=Disappearance of all target lesions; disappearance of all nontarget lesions. PD=At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
Time frame: Up to 2.2 years
Phase 2: Disease Control Rate (DCR) at 6 Cycles (28-Day Cycles) as Assessed by the Investigator
DCR was defined as the percentage of participants with objective evidence of confirmed CR, confirmed PR, or SD according to RECIST version 1.1 criteria as assessed by investigator. CR=disappearance of all target lesions; disappearance of non-target lesions. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. PD=At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
Time frame: Up to 2.2 years
Phase 2: Overall Response Rate (ORR) as Assessed by the Investigator
ORR was defined as the percentage of participants who achieved a best overall response of PR or CR according to RECIST v1.1 criteria as assessed by investigator. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. CR=Disappearance of all target lesions; disappearance of all nontarget lesions.
Time frame: Up to 2.2 years
Phase 2: DOR as Assessed by the Investigator
DOR was defined as the time from the first documented response (CR or PR) to the first documented objective PD or death due to any case according to RECIST v1.1 criteria as assessed by investigator. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. CR=Disappearance of all target lesions; disappearance of all nontarget lesions. PD=At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
Time frame: Up to 2.2 years
| Milestone | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule | Phase 1b: Revumenib 270 mg Tablet |
|---|---|---|---|---|
| Started | 3 | 10 | 6 | 22 |
| Received at least 1 dose of study drug | 3 | 10 | 6 | 22 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 3 | 10 | 6 | 22 |
| Withdrew: Death | 3 | 8 | 5 | 15 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 1 | 7 |
DLT was defined as any of the following occurring in Cycle 1: Grade 4 neutropenia (absolute neutrophil count \[ANC\] \<500 cells/mm\^3) unresolved to Grade 2 (ANC \>1500 cells/mm\^3) or baseline for more than 7 consecutive days in the absence of growth factor support, ≥Grade 3 neutropenia (ANC \<1000 cells/mm\^3) with a single temperature of \>38.3°Celsius (101°Fahrenheit) or a sustained temperature of ≥38°Celsius (100.4°Fahrenheit) for more than 1 hour, Grade 4 thrombocytopenia (\<25,000/mm\^3) of any duration, ≥Grade 3 thrombocytopenia (\<50,000/mm\^3) with clinically significant bleeding, Grade 4 anemia (i.e, life-threatening consequences; urgent intervention indicated) or ≥Grade 3 nonhematologic toxicity as defined in Common Terminology Criteria for Adverse Events version 5.0 scale where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, medically significant, Grade 4=Life-threatening and 5=Death.
| Participants | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule |
|---|---|---|---|
| Phase 1a: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study intervention, whether or not considered related to the study intervention. TEAEs were defined as those having an onset on or after the first dose of revumenib or a sign, symptom, or a diagnosis that worsened on or after first dose of revumenib but no later than 30 days after the date of the last dose of revumenib. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule | Phase 1b: Revumenib 270 mg Tablet |
|---|---|---|---|---|
| Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 3 | 8 | 6 | 22 |
DCR was defined as the percentage of participants with objective evidence of confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) according to Response Evaluation in Solid Tumors (RECIST) version 1.1 criteria as assessed by the investigator. CR=disappearance of all target lesions; disappearance of non-target lesions. PR=At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. PD=At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
| percentage of participants | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule | Phase 1b: Revumenib 270 mg Tablet |
|---|---|---|---|---|
| Phase 1: Disease Control Rate (DCR) | 0 (0.0 to 70.8) | 25.0 (3.2 to 65.1) | 33.3 (4.3 to 77.7) | 10.0 (1.2 to 31.7) |
ORR was defined as the percentage of participants who achieved a best overall response of PR or CR according to RECIST v1.1 criteria as assessed by the investigator. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. CR=Disappearance of all target lesions; disappearance of all nontarget lesions.
| percentage of participants | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule | Phase 1b: Revumenib 270 mg Tablet |
|---|---|---|---|---|
| Phase 1: Overall Response Rate (ORR) | 0 (0.0 to 70.8) | 0 (0.0 to 36.9) | 0 (0.0 to 45.9) | 0 (0.0 to 16.8) |
PFS was defined as the time from the first dosing date to the first documented progression or death due to any cause, whichever occurred first.
No measurements were reported for this outcome.
| nanograms per milliliter (ng/mL) | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule |
|---|---|---|---|
| Cycle 1 Day 7 | 2525 ± 26.2 | 3092 ± 69.4 | 4078 ± 43.2 |
| Cycle 1 Day 14 | 2174 ± 24.5 | 2312 ± 73.0 | 3286 ± 44.4 |
| Cycle 2 Day 8 | 3786 ± 9.9 | 3436 ± 52.2 | 2762 ± 99.1 |
| Cycle 2 Day 15 | 2983 ± 10.0 | 3178 ± 86.6 | 4404 ± 65.7 |
| Cycle 5 Day 1 | — | 1190 | 3940 |
| ng/mL | Phase 1b: Revumenib 270 mg Tablet |
|---|---|
| Cycle 1 Day 7 | 3225 ± 58.6 |
| Cycle 1 Day 14 | 3014 ± 56.6 |
| Cycle 2 Day 8 | 3952 ± 56.3 |
| Cycle 2 Day 15 | 2237 ± 66.7 |
| hours*nanograms/milliliter | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule |
|---|---|---|---|
| Cycle 1 Day 7 | 12210 ± 25.1 | 14600 ± 53.4 | 17010 ± 37.4 |
| Cycle 1 Day 14 | 9202 ± 21.8 | 11580 ± 77.4 | 16200 ± 48.3 |
| Cycle 2 Day 8 | 14220 ± 3.9 | 16520 ± 61.0 | 13900 ± 91.2 |
| Cycle 2 Day 15 | 11700 ± 0.7 | 14840 ± 90.4 | 19580 ± 58.6 |
| Cycle 5 Day 1 | — | 6904 | 22640 |
| hours | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule |
|---|---|---|---|
| Cycle 1 Day 7 | 2.117 (2.03 to 4.00) | 1.033 (0.483 to 2.02) | 0.9333 (0.467 to 0.967) |
| Cycle 1 Day 14 | 2.050 (2.03 to 2.07) | 2.017 (1.95 to 3.80) | 2.050 (1.83 to 3.85) |
| Cycle 2 Day 8 | 1.242 (0.500 to 1.98) | 0.9333 (0.433 to 1.92) | 0.9833 (0.00 to 2.08) |
| Cycle 2 Day 15 | 1.242 (0.500 to 1.98) | 0.9667 (0.933 to 1.92) | 1.000 (0.450 to 3.85) |
| Cycle 5 Day 1 | — | 4.000 (4.00 to 4.00) | 3.78 (3.78 to 3.78) |
| hours | Phase 1b: Revumenib 270 mg Tablet |
|---|---|
| Cycle 1 Day 7 | 1.967 (0.500 to 5.75) |
| Cycle 1 Day 14 | 2.150 (1.92 to 4.12) |
| Cycle 2 Day 8 | 1.008 (0.500 to 2.00) |
| Cycle 2 Day 15 | 1.042 (0.00 to 4.03) |
| h*ng/mL | Phase 1b: Revumenib 270 mg Tablet |
|---|---|
| Cycle 1 Day 7 | 16400 ± 68.2 |
| Cycle 1 Day 14 | 16680 ± 80.6 |
| Cycle 2 Day 8 | 15610 ± 83.0 |
| Cycle 2 Day 15 | 10620 ± 114.0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study intervention, whether or not considered related to the study intervention. TEAEs were defined as those having an onset on or after the first dose of revumenib or a sign, symptom, or a diagnosis that worsened on or after first dose of revumenib but no later than 30 days after the date of the last dose of revumenib. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
No measurements were reported for this outcome.
OS was defined as the time from the date of first dosing of revumenib to death due to any cause.
No measurements were reported for this outcome.
DCR was defined as the percentage of participants with objective evidence of confirmed CR, confirmed PR, or SD according to RECIST version 1.1 criteria as assessed by blinded radiographic review. CR=disappearance of all target lesions; disappearance of non-target lesions. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. PD=At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
No measurements were reported for this outcome.
ORR was defined as the percentage of participants who achieved a best overall response of PR or CR according to RECIST v1.1 criteria as assessed by blinded radiographic review. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. CR=Disappearance of all target lesions; disappearance of all nontarget lesions.
No measurements were reported for this outcome.
DOR was defined as the time from the first documented response (CR or PR) to the first documented objective PD or death due to any case according to RECIST v1.1 criteria as assessed by blinded radiographic review. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. CR=Disappearance of all target lesions; disappearance of all nontarget lesions. PD=At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
No measurements were reported for this outcome.
DCR was defined as the percentage of participants with objective evidence of confirmed CR, confirmed PR, or SD according to RECIST version 1.1 criteria as assessed by investigator. CR=disappearance of all target lesions; disappearance of non-target lesions. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. PD=At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
No measurements were reported for this outcome.
ORR was defined as the percentage of participants who achieved a best overall response of PR or CR according to RECIST v1.1 criteria as assessed by investigator. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. CR=Disappearance of all target lesions; disappearance of all nontarget lesions.
No measurements were reported for this outcome.
DOR was defined as the time from the first documented response (CR or PR) to the first documented objective PD or death due to any case according to RECIST v1.1 criteria as assessed by investigator. PR=At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. CR=Disappearance of all target lesions; disappearance of all nontarget lesions. PD=At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
No measurements were reported for this outcome.
Collected over Up to 2.2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | 8/10 (80%) | 2/10 (20%) | 8/10 (80%) |
| Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule | 5/6 (83.3%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase 1b: Revumenib 270 mg Tablet | 15/22 (68.2%) | 6/22 (27.3%) | 22/22 (100%) |
| Event | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule | Phase 1b: Revumenib 270 mg Tablet |
|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 1/3 | 0/10 | 0/6 | 2/22 |
| Procedural painInjury, poisoning and procedural complications | 1/3 | 0/10 | 0/6 | 0/22 |
| Acute kidney injuryRenal and urinary disorders | 1/3 | 0/10 | 0/6 | 0/22 |
| PyrexiaGeneral disorders | 0/3 | 0/10 | 1/6 | 0/22 |
| Urinary tract obstructionRenal and urinary disorders | 0/3 | 0/10 | 1/6 | 0/22 |
| Deep vein thrombosisVascular disorders | 0/3 | 0/10 | 1/6 | 0/22 |
| Abdominal painGastrointestinal disorders | 0/3 | 0/10 | 0/6 | 3/22 |
| OedemaGeneral disorders | 0/3 | 1/10 | 0/6 | 0/22 |
| Atrial fibrillationCardiac disorders | 0/3 | 1/10 | 0/6 | 0/22 |
| Large intestinal obstructionGastrointestinal disorders | 0/3 | 0/10 | 0/6 | 1/22 |
| Event | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule | Phase 1b: Revumenib 270 mg Tablet |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/3 | 1/10 | 5/6 | 10/22 |
| VomitingGastrointestinal disorders | 0/3 | 2/10 | 4/6 | 8/22 |
| FatigueGeneral disorders | 1/3 | 1/10 | 3/6 | 5/22 |
| Electrocardiogram QT prolongedInvestigations | 0/3 | 2/10 | 0/6 | 9/22 |
| DysgeusiaNervous system disorders | 0/3 | 4/10 | 2/6 | 5/22 |
| Abdominal distensionGastrointestinal disorders | 1/3 | 1/10 | 1/6 | 5/22 |
| ConstipationGastrointestinal disorders | 1/3 | 1/10 | 0/6 | 4/22 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 1/10 | 2/6 | 3/22 |
| Abdominal painGastrointestinal disorders | 1/3 | 0/10 | 0/6 | 3/22 |
| Abdominal pain upperGastrointestinal disorders | 1/3 | 0/10 | 0/6 | 1/22 |
Safety population consisted of all enrolled participants who received at least 1 dose of study treatment during the study.
| Age, Continuous(years) | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule | Phase 1b: Revumenib 270 mg Tablet | Total |
|---|---|---|---|---|---|
| Mean | 62.3 ± 9.87 | 57.9 ± 10.37 | 56.5 ± 15.10 | 57.1 ± 14.31 | 57.6 ± 12.92 |
| Sex: Female, Male(Participants) | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule | Phase 1b: Revumenib 270 mg Tablet | Total |
|---|---|---|---|---|---|
| Female | 1 | 4 | 3 | 10 | 18 |
| Male | 2 | 6 | 3 | 12 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule | Phase 1b: Revumenib 270 mg Tablet | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 3 | 3 |
| Not Hispanic or Latino | 3 | 10 | 5 | 17 | 35 |
| Unknown or Not Reported | 0 | 0 | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Phase 1a: Revumenib 160 mg Tablet or 163 mg Capsule | Phase 1a: Revumenib 220 mg Tablet or 226 mg Capsule | Phase 1a: Revumenib 270 mg Tablet or 276 mg Capsule | Phase 1b: Revumenib 270 mg Tablet | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 1 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 1 |
| White | 3 | 9 | 3 | 19 | 34 |
| More than one race | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2023 to primary completion in Jun 2025, 26 months.
Results were first posted in Jul 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Revumenib